Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells

Abstract

Background:

Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) effectively lead to reduction in disease relapses and active magnetic resonance imaging (MRI) lesions. DMF and MMF are known to be effective in modulating T- and B-cell responses; however, their effect on the phenotype and function of human myeloid dendritic cells (mDCs) is not fully understood.

Objective:

To investigate the role of MMF on human mDCs maturation and function.

Methods:

mDCs from healthy controls were isolated and cultured in vitro with MMF. The effect of MMF on mDC gene expression was determined by polymerase chain reaction (PCR) array after in vitro MMF treatment. The ability of mDCs to activate T cells was assessed by in vitro co-culture system. mDCs from DMF-treated multiple sclerosis (MS) patients were analyzed by flow cytometry and PCR.

Results:

MMF treatment induced a less mature phenotype of mDCs with reduced expression of major histocompatibility complex class II (MHC-II), co-stimulatory molecules CD86, CD40, CD83, and expression of nuclear factor κB (NF-κB) subunits RELA and RELB. mDCs from DMF-treated MS patients also showed the same immature phenotype. T cells co-cultured with MMF-treated mDCs showed reduced proliferation with decreased production of interferon gamma (IFN-γ), interleukin-17 (IL-17), and granulocyte-macrophage colony-stimulating factor (GM-CSF) compared to untreated cells.

Conclusion:

We report that MMF can modulate immune response by affecting human mDC function.

Keywords

Multiple sclerosis myeloid dendritic cells dimethyl fumarate monomethyl fumarate NF-kB co-stimulatory molecules

Get full access to this article

View all access options for this article.

References

Compston

Coles

Multiple sclerosis. Lancet 2008; 372(9648): 1502–1517.

Serafini

Rosicarelli

Magliozzi

et al . Dendritic cells in multiple sclerosis lesions: Maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol 2006; 65(2): 124–141.

Vaknin-Dembinsky

Balashov

Weiner

HL.

IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006; 176(12): 7768–7774.

Karni

Abraham

Monsonego

et al . Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006; 177(6): 4196–4202.

Fox

Miller

Phillips

et al . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367(12): 1087–1097.

Gold

Kappos

Arnold

et al . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098–1107.

Scannevin

Chollate

Jung

et al . Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012; 341(1): 274–284.

Linker

Lee

Ryan

et al . Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134(Pt 3): 678–692.

Treumer

Zhu

Glaser

et al . Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121(6): 1383–1388.

10.

Spencer

Crabtree-Hartman

Lehmann-Horn

et al . Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2015; 2(3): e76.

11.

Longbrake

Ramsbottom

Cantoni

et al . Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler 2016; 22(8): 1061–1070.

12.

Tahvili

Zandieh

Amirghofran

The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis. Int J Dermatol 2015; 54(7): e254–e260.

13.

Gross

Schulte-Mecklenbeck

Klinsing

et al . Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3(1): e183.

14.

Gerdes

Shakery

Mrowietz

Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007; 156(5): 838–842.

15.

Peng

Guerau-de-Arellano

Mehta

et al . Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012; 287(33): 28017–28026.

16.

Ghoreschi

Bruck

Kellerer

et al . Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208(11): 2291–2303.

17.

Litjens

Rademaker

Ravensbergen

et al . Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol 2006; 154(2): 211–217.

18.

Andersson

Cirkic

Hellman

et al . Myeloid blood dendritic cells and monocyte-derived dendritic cells differ in their endocytosing capability. Hum Immunol 2012; 73(11): 1073–1081.

19.

Osugi

Vuckovic

Hart

DN.

Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002; 100(8): 2858–2866.

20.

Litjens

Burggraaf

Van Strijen

et al . Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004; 58(4): 429–432.

21.

Ruggieri

Tortorella

Gasperini

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag 2014; 10: 229–239.

22.

Mazzola

Raheja

Murugaiyan

et al . Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. J Neuroinflammation 2015; 12: 245.

23.

Kramer

Green

Pollard

et al . Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014; 30(4): 523–530.

24.

Arthur

Ley

SC.

Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13(9): 679–692.

25.

Jackson

Mulcahy

Porte

et al . Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of T H-responses. Eur Cytokine Netw 2010; 21(4): 319–328.

26.

Dalod

Chelbi

Malissen

et al . Dendritic cell maturation: Functional specialization through signaling specificity and transcriptional programming. EMBO J 2014; 33(10): 1104–1116.

27.

Seillet

Belz

GT.

Terminal differentiation of dendritic cells. Adv Immunol 2013; 120: 185–210.

28.

Hoesel

Schmid

JA.

The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.

29.

Schlitzer

McGovern

Teo

et al . IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013; 38(5): 970–983.

30.

Sozzani

Allavena

D’Amico

et al . Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties. J Immunol 1998; 161(3): 1083–1086.

31.

Sallusto

Schaerli

Loetscher

et al . Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28(9): 2760–2769.

32.

Kivisakk

Mahad

Callahan

et al . Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann Neurol 2004; 55(5): 627–638.

33.

Brucklacher-Waldert

Stuerner

Kolster

et al . Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009; 132(Pt 12): 3329–3341.

34.

Jager

Dardalhon

Sobel

et al . Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009; 183(11): 7169–7177.

35.

Serpero

Filaci

Parodi

et al . Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol 2013; 8(5): 1106–1113.

36.

Durelli

Conti

Clerico

et al . T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009; 65(5): 499–509.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB

0.08 MB